Scarica l'app Stockscreener
4.59
1.55%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.52
Aprire:
$4.51
Volume 24 ore:
157.13K
Relative Volume:
0.86
Capitalizzazione di mercato:
$238.31M
Reddito:
$3.50M
Utile/perdita netta:
$-80.40M
Rapporto P/E:
-1.7852
EPS:
-2.5711
Flusso di cassa netto:
$-29.83M
1 W Prestazione:
+0.22%
1M Prestazione:
-15.16%
6M Prestazione:
+33.43%
1 anno Prestazione:
+148.11%
Intervallo 1D:
$4.50
$4.95
Intervallo di 1 settimana:
$4.39
$5.0935
Portata 52W:
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
617-651-8867
Indirizzo
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.59 | 238.31M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Iniziato | Wedbush | Outperform |
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | William Blair | Outperform |
| 2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2021-09-24 | Reiterato | Craig Hallum | Buy |
| 2021-06-25 | Reiterato | Craig Hallum | Buy |
| 2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-05 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-01 | Reiterato | Craig Hallum | Buy |
| 2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2018-12-14 | Reiterato | B. Riley FBR | Buy |
| 2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Iniziato | Goldman | Neutral |
| 2018-10-15 | Iniziato | Jefferies | Hold |
| 2018-09-28 | Reiterato | Craig Hallum | Hold |
| 2018-04-27 | Reiterato | Craig Hallum | Hold |
| 2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress - Investing.com
CAMP PE Ratio & Valuation, Is CAMP Overvalued - Intellectia AI
Aug Swings: Should value investors consider Camp4 Therapeutics Corporation2026 Earnings Surprises & Daily Entry Point Alerts - baoquankhu1.vn
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks
CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart
CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com Australia
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation By Investing.com - Investing.com South Africa
CAMP4 Therapeutics appoints Michael MacLean to board of directors - investing.com
CAMP4 Therapeutics appoints Michael MacLean to board of directors By Investing.com - Investing.com UK
Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union
New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan
If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan
Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan
EVTL Technical Analysis & Price Forecast - Intellectia AI
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target - Investing.com India
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target By Investing.com - Investing.com Australia
CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress - TipRanks
Camp4 Therapeutics Corp posts full year 2025 financial results and unveils corporate update - Traders Union
Camp4 Therapeutics Earnings Review: Q4 Summary - Benzinga
Camp4 Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights - GlobeNewswire
Guidance Update: What is Camp4 Therapeutics Corporations book value per shareEarnings Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines - Traders Union
Camp4 Therapeutics Corporation announced that it has received $100.167156 million in funding from Janus Henderson Investors, Balyasny Asset Management L.P., Vivo Capital, LLC, Adage Capital Management, L.P., Trails Edge Capital Partners, LLC, SYN - marketscreener.com
Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment - Traders Union
Camp4 Therapeutics Corp commits to new therapies for rare and neurological diseases - Traders Union
CAMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
RBOT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Merger Talk: Whats next for Mondelez International Inc stockQuarterly Profit Review & Verified Chart Pattern Signals - baoquankhu1.vn
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Camp 4 Therapeutics Corp Azioni (CAMP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):